-
公开(公告)号：US20220356230A1
公开(公告)日：2022-11-10
申请号：US17207524
申请日：2021-03-19
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Robert Babb , Alina BAUM , Gang CHEN , Cindy GERSON , Johanna HANSEN , Tammy HUANG , Christos KYRATSOUS , Wen-Yi LEE , Marine MALBEC , Andrew MURPHY , William OLSON , Neil STAHL , George D. YANCOPOULOS
IPC: C07K16/10 , A61K45/06 , A61K39/395 , A61K39/15
Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).
-
公开(公告)号：US20210347852A1
公开(公告)日：2021-11-11
申请号：US17314503
申请日：2021-05-07
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： William OLSON , Joel MARTIN , Neil STAHL , Jee KIM
Abstract: The present relates to VEGF traps and VEGF mini-traps that include VEGF receptor Ig-like domains, fused to a multimerizing component, which bind to VEGF and block its interaction with the VEGF receptor. Such molecules are useful for treating angiogenic eye disorders (e.g., age-related macular degeneration), cancer and for other undesired angiogenesis.
-
公开(公告)号：US20220195058A1
公开(公告)日：2022-06-23
申请号：US17554276
申请日：2021-12-17
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： Michael DUNN , Lori MORTON , Neil STAHL , Tammy HUANG , Ishita CHATTERJEE , Vishal KAMAT , Ashique RAFIQUE
Abstract: The present disclosure provides novel immunoglobulin proteins that bind to a human natriuretic peptide receptor 1 (NPR1) agonist, preferably an anti-NPR1 antibody. In certain embodiments, the proteins of the disclosure comprise at least one immunoglobulin variable domain that binds to an anti-NPR1 antibody. In certain embodiments, the proteins of the disclosure are useful in blocking and/or reversing the effect of an administered anti-NPR1 antibody. In certain embodiments, the antigen-binding proteins are useful for effective management of blood pressure and hemodynamics in humans.
-
4.发明申请Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitor 审中-公开通过施用IL-4R抑制剂治疗过敏和增强变应原特异性免疫治疗的方法公开(公告)号：US20140356372A1
公开(公告)日：2014-12-04
申请号：US14294544
申请日：2014-06-03
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： Neil STAHL , Jamie M. ORENGO , Andrew J. MURPHY , Namita GANDHI , Neil GRAHAM
IPC: C07K16/28 , A61K45/06 , A61K39/395
CPC classification number: C07K16/2866 , A61K39/395 , A61K45/06 , A61K2039/505 , A61K2039/577 , A61P37/02 , A61K2300/00
Abstract: The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and/or safety of an allergen-specific immunotherapy (SIT) regimen. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4Rα) antagonist such as an anti-IL-4Rα antibody.
Abstract translation: 本发明提供了治疗，预防或降低过敏反应的严重性的方法。 本发明还提供了增强变应原特异性免疫治疗（SIT）方案的功效和/或安全性的方法。 本发明的方法包括向有需要的受试者施用包含白细胞介素-4受体（IL-4Rα）拮抗剂如抗IL-4Rα抗体的治疗组合物。
-
公开(公告)号：US20230348569A1
公开(公告)日：2023-11-02
申请号：US18216118
申请日：2023-06-29
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Robert BABB , Alina BAUM , Gang CHEN , Cindy GERSON , Johanna HANSEN , Tammy HUANG , Christos KYRATSOUS , Wen-Yi LEE , Marine MALBEC , Andrew MURPHY , William OLSON , Neil STAHL , George D. YANCOPOULOS
IPC: C07K16/10 , A61K45/06 , A61K39/395 , A61K39/15
CPC classification number: C07K16/10 , A61K45/06 , A61K39/395 , A61K39/15 , C07K2317/31 , C07K2317/52 , C07K2317/565
Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).
-
Patent Agency Ranking
公开(公告)号：US20170260293A1
公开(公告)日：2017-09-14
申请号：US15601614
申请日：2017-05-22
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： George D. YANCOPOULOS , Nicholas J. PAPADOPOULOS , Neil STAHL , Samuel DAVIS , Andrew J. MURPHY , Lynn MACDONALD
CPC classification number: C07K16/468 , C07K16/2803 , C07K16/2809 , C07K16/2887 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/52 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/569 , C07K2317/622 , C07K2317/64
Abstract: Multivalent antigen-binding proteins comprising two or three or four or more immunoglobulin heavy chain variable domain binding domains are provided, as are methods for making them, nucleic acid constructs, and cell lines for making them. Proteins comprising two or three or four or more different heavy chain variable domains that lack an immunoglobulin variable domain are provided. Proteins comprising two or three or four or more different heavy chain variable domains that associate with the same immunoglobulin light chain variable domain are also provided.
-
7.发明公开公开(公告)号：US20230159647A1
公开(公告)日：2023-05-25
申请号：US17935003
申请日：2022-09-23
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： Neil STAHL , Jamie M. ORENGO , Andrew J. MURPHY , Namita GANDHI , Neil GRAHAM
IPC: C07K16/28 , A61K45/06 , A61P37/02 , A61K39/395
CPC classification number: C07K16/2866 , A61K45/06 , A61P37/02 , A61K39/395 , A61K2039/505
Abstract: The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and/or safety of an allergen-specific immunotherapy (SIT) regimen. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4Rα) antagonist such as an anti-IL-4Rα antibody.
-
公开(公告)号：US20190351049A1
公开(公告)日：2019-11-21
申请号：US16530140
申请日：2019-08-02
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Christos KYRATSOUS , Neil STAHL , Sumathi SIVAPALASINGAM
IPC: A61K39/215 , G01N33/569 , C07K14/165 , A61K45/06 , A61K39/12 , C07K16/10
Abstract: The present invention provides monoclonal antibodies that bind to the Middle East Respiratory Syndrome—Coronavirus (MERS-CoV) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to MERS-CoV spike protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing MERS-CoV activity, thus providing a means of treating or preventing MERS infection in humans. In some embodiments, the invention provides for a combination of one or more antibodies that bind to the MERS-CoV spike protein for use in treating MERS infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the MERS-CoV spike protein.
-
公开(公告)号：US20170247474A1
公开(公告)日：2017-08-31
申请号：US15345161
申请日：2016-11-07
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： George D. YANCOPOULOS , Nicholas J. PAPADOPOULOS , Neil STAHL , Samuel DAVIS , Andrew J. MURPHY , Lynn MACDONALD
CPC classification number: C07K16/468 , C07K16/2803 , C07K16/2809 , C07K16/2887 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/52 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/569 , C07K2317/622 , C07K2317/64
Abstract: Multivalent antigen-binding proteins comprising two or three or four or more immunoglobulin heavy chain variable domain binding domains are provided, as are methods for making them, nucleic acid constructs, and cell lines for making them. Proteins comprising two or three or four or more different heavy chain variable domains that lack an immunoglobulin variable domain are provided. Proteins comprising two or three or four or more different heavy chain variable domains that associate with the same immunoglobulin light chain variable domain are also provided.
-
公开(公告)号：US20140044730A1
公开(公告)日：2014-02-13
申请号：US13964159
申请日：2013-08-12
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： George D. YANCOPOULOS , Nicholas J. PAPADOPOULOS , Andrew J. MURPHY , Neil STAHL
IPC: C07K16/40
CPC classification number: C07K16/40 , A61K2039/505 , C07K2317/21 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: The present invention provides antibodies and antigen-binding fragments thereof that specifically bind proprotein convertase subtilisin/kexin-9 (PCSK9) with greater affinity at neutral pH than at acidic pH. The antibodies of the invention may possess one or more amino acid changes as compared to antibodies that do not exhibit pH-dependent binding properties. For example, the present invention includes anti-PCSK9 antibodies which possess one or more histidine substitutions in one or more complementarity determining regions. The antibodies of the invention, with pH-dependent binding properties, remain in circulation and exhibit cholesterol lowering activity for prolonged periods of time in animal subjects as compared to anti-PCSK9 antibodies that do not exhibit pH-dependent binding properties. The antibodies of the invention are therefore useful for treating diseases and disorders related to elevated HDL cholesterol, wherein the antibodies of the invention can be administered to a patient at a lower dose and/or with less frequent dosing as compared to antibodies that do not exhibit pH-dependent binding properties.
Abstract translation: 本发明提供了在中性pH下比在酸性pH下具有更高亲和力特异性结合前蛋白转化酶枯草杆菌蛋白酶/ kexin-9（PCSK9）的抗体及其抗原结合片段。 与不显示pH依赖性结合特性的抗体相比，本发明的抗体可具有一个或多个氨基酸变化。 例如，本发明包括在一个或多个互补决定区具有一个或多个组氨酸取代的抗PCSK9抗体。 与不具有pH依赖性结合性质的抗PCSK9抗体相比，具有pH依赖性结合特性的本发明的抗体在动物受试者中保持循环并显示长时间的胆固醇降低活性。 因此，本发明的抗体可用于治疗与升高的HDL胆固醇相关的疾病和病症，其中与不显示的抗体相比，本发明的抗体可以较低剂量和/或以较不频繁的给药方式施用于患者 pH依赖性结合性质。
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.019 seconds)
